Safety and efficiency of molnupiravir for COVID-19 patients with

molnupiravir dose  Usual dose: 800 mgtime, orally x 2 timesday, duration of treatment: 5 days Molnupiravir is used after eating, the patient should pay attention to take the Conclusion Molnupiravir was safe and well tolerated; a dose of 800mg twice-daily for 5 days was recommended for Phase II evaluation

In terms of safety, the most common side effects reported during treatment and within 14 days after the last dose of Lagevrio were diarrhoea 68% of patients in the molnupiravir group had received at least three doses of mRNA vaccine or two doses of the S vaccine

Patients were randomized to receive molnupiravir 800 mg PO twice daily for 5 days plus usual care or usual care alone The primary endpoint was If you cannot swallow capsules whole, tell your healthcare provider What do I do if I miss a dose of LAGEVRIO? If it has been less